September 27, 2016 1:07 PM ET

Life Sciences Tools and Services

Company Overview of WaveSense, Inc.

Company Overview

WaveSense, Inc. engages in the development, manufacture, and marketing of analytical nanotechnologies for use in cellular and molecular assay markets. The company offers EpiSep, a lateral flow separations platform that is used for the detection and characterization of live cells, proteins, and genes. It also provides EpiSep slides, super paramagnetic particles, conjugate antibodies, preserved tumor cells, buffers, start up kits, ready-to-use kits, and accessories. The company offers its products for drug discovery and rare cell detection in blood and bone marrow, as well as for infectious disease, bio-defense, veterinary diagnostic, and regenerative medicine test applications. Its products a...

15339 Barranca Parkway

Irvine, CA 92618

United States

Founded in 1999

Phone:

949-341-1980

Fax:

949-341-1982

Key Executives for WaveSense, Inc.

Chief Executive Officer
Founder and Chief Technology Officer
Founder and Director
Age: 70
Compensation as of Fiscal Year 2016.

WaveSense, Inc. Key Developments

WaveSense Appoints Jack L. McGinley as New Chairman

WaveSense appointed Jack L. McGinley as its new chairman. Prior to co-founding RoundTable Healthcare Partners in 2001, McGinley spent 30 years in senior management at Baxter International, departing as executive vice president. In addition, William W. Curtis was appointed chief executive officer to develop and implement the company's new strategic commercialization plan.

WaveSense, Inc. Announces Launch of a New Application that Targets, Enriches and Isolates Cells Obtained from DRE/DRM

WaveSense, Inc. announced the availability of the latest addition to its line of cell enrichment applications delivered through its patented EpiSep medical product line. The Cell Enrichment from Expressed Prostate Secretions application captures, enriches and isolates targeted cells contained in prostate secretions obtained through digital rectal examination (DRE) or digital rectal massage (DRM). The EPS application is an important new addition to the WaveSense's Urology application suite that already includes cell enrichment from urine. The Cell Enrichment from Expressed Prostate Secretions application is the latest addition to a growing list of EpiSep HStargeted cell enrichment and isolation applications, including its Cell Enrichment from Urine (Uro-1) and Cell Enrichment from Bone Marrow (CD138) applications.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact WaveSense, Inc., please visit www.wavesense.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.